To promote the new diabetes drug Byetta (aka Exenatide injection), Eli Lilly & Co. and partner Amylin Pharmaceuticals are featuring this guy, the Gila monster, during TV interviews today with the drug's discoverer and a diabetes doctor. The drug is of course the one derived from the saliva of this venomous lizard.
Byetta seems to have exciting possiblities to increase insulin secretion in Type 2 diabetics, but once again, you will find most press coverage in the Finance Section of the newspaper: Business Week says Eli Lilly's "flowering of new diabetes drugs" will put it ahead of the competition.
Furthermore, the company is expected to "raise its profile in the diabetes arena" this coming weekend at the American Diabetes Association's annual scientific sessions in San Diego, CA. That's the big annual conference, expected to attract more than 13,500 researchers and doctors this year!
And guess who will be there? Yup, this little 'ol diabetes blogger personally. The whole thing happened so fast, I've hardly got time to pack my test strips. But I'm off to San Diego tomorrow to see what I shall see.
American Diabetes Association Names New CEO
Non-profit leader Kevin L. Hagan named as new chief exec of national diabetes org after six-month search.
FDA Approves New Basal Insulin
Sanofi's Troujeo has 'flatter profile' of action that helps to avoid lows.
Daytona Win for Racecar Driver with Diabetes!
Type 1 driver Ryan Reed wins first NASCAR series race at Daytona on Feb. 21.